Interferon no better than Observation

This moderated forum is to support the needs of patients with stage III melanoma, as well as to answer questions about treatment options and what to expect.

Interferon no better than Observation

Postby Linny » Wed Feb 01, 2017 9:42 pm

IFN Induction No Better Than Observation for Intermediate-risk Melanoma

Induction therapy with intravenous interferon-α-2b was no better than observation alone with respect to relapse-free survival and overall survival for the management of patients with intermediate-risk melanoma, a study published in the Journal of Clinical Oncology has shown.

Interferon-α-2b is approved as adjuvant therapy for patients with high-risk surgically resected stage IIB and III melanoma as an intravenous infusion given for 5 days per week for 4 weeks followed by 3 days per week for 11 months. Investigators hypothesized that the major source of benefit from the interferon regimen may be due to the initial induction therapy administered over 4 weeks.

To evaluate the efficacy of 4 weeks of intravenous induction with high-dose interferon compared with observation in patients with surgically resected intermediate-risk melanoma, investigators enrolled 1150 patients with T2bN0, T3a-bN0, T4a-bN0, or T1-4N1a-2a (microscopic) cutaneous melanoma who had undergone surgical resection.

For the international, open-label, phase 3 trial (ClinicalTrials.gov Identifier: NCT00003641), investigators randomly assigned patients to receive interferon-α-2b for 5 days every week for 4 weeks or observation alone.

At a median follow-up of 7 years, results showed no significant differences in the 5-year relapse-free survival rate (P = .964) or 5-year overall survival rate (P = .558) between the 2 treatment arms.

At 5 years, 70% (95% CI, 66-74) of patients in the interferon arm and 70% (95% CI, 66-74) of those in the observation arm were free of relapse. Similarly, 83% (95% CI, 80-86) of patients who received interferon induction and 83% (95% CI, 79-86) of those who received observation were alive at 5 years.

However, researchers found that significantly fewer patients in the observation arm experienced treatment-related grade 3 or worse adverse events than those in the interferon arm (4.6% vs 57.9%; P < .001). Further, quality of life was poorer for the interferon-treated patients.

http://www.oncologynurseadvisor.com/melanoma/induction-therapy-confers-no-additional-survival-benefit-for-intermediate-risk-melanoma/article/635136/
Stage III, Unknown Primary; 1 positive node in left axilla
Linny
 
Posts: 315
Joined: Fri Feb 03, 2012 9:24 pm

Re: Interferon no better than Observation

Postby Catherine Poole » Fri Feb 03, 2017 8:56 am

No surprise to us here! Thanks Linny
Catherine M. Poole, President/Founder
Melanoma International Foundation
Catherine Poole
 
Posts: 10775
Joined: Wed Jan 02, 2008 12:09 am

Re: Interferon no better than Observation

Postby Linny » Fri Feb 03, 2017 10:06 am

Definitely no surprise. Nice to see it in print, though.
Stage III, Unknown Primary; 1 positive node in left axilla
Linny
 
Posts: 315
Joined: Fri Feb 03, 2012 9:24 pm


Return to Melanoma: Stage III

Who is online

Registered users: Bing [Bot], Majestic-12 [Bot]

cron